News
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
IMV to Present at Raymond James' Human Health Innovation Conference
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today announced
Nanobiotix Secures €10M in Non-Dilutive Financing
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
Aurinia Announces Results of Annual General Meeting
Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the nine incumbent directors of the Company were elected at the Company’s annual
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Recapitalisation Led by Sophisticated Life Sciences Investor - Apeiron Investment Group Ltd
Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical stage biopharmaceutical company, today announced that it has entered into a Subscription Agreement, with Apeiron
Albireo Pharma: Jubiläumstipp immer höher – wann fliegt die Decke weg?
Zu unserem zehnjährigen Jubiläum stellten wir Dir Albireo Pharma (WKN: A2DF99) als Gratis-Rakete mit einem Chance-Risiko-Verhältnis vor, wie es sonst nur in unserem exklusiven No Brainer Club (NBC)
Neueste NBC-Empfehlungen knallen +94% und +41% in wenigen Wochen
Kaum ist der neue Monat angebrochen, knallt es wieder in den NBC-Depots und die Cashberge der Mitglieder erreichen neue Allzeithochs: Mit MEI Pharma (WKN: A1KATX) und Pfenex (WKN: A118RA) schießen
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat
Nanobiotix Announces Positive First Results From Phase I Expansion in Locally Advanced Head and Neck Cancer at ASCO 2020
Regulatory News:
NANOBIOTIX (Paris:NANO)(Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m
Clinical Response and Translational Data from DeCidE1, a Phase 2 Study of DPX-Survivac Immunotherapy in Patients with Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reported
Paion, Evotec, Aurora Cannabis: 3 Perlen für 2020?
Paion (WKN: A0B65S) nähert sich der wegweisenden Marktzulassung seines Anästhetikums in den USA. Die Entscheidung fällt am 5. Juli. Die überwiegend wahrscheinliche Zulassung würde für das
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the National Comprehensive Cancer Network® (NCCN) updated its Clinical Practice Guidelines in Oncology for Prostate Cancer to include new
Savara to Present at the Jefferies Virtual Healthcare Conference
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at
Transgene: Combined General Meeting of May 27, 2020
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 27, 2020) at 10:00 a.m. at the Company's headquarters (400
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that six abstracts featuring data from clinical and real-world evidence studies evaluating Rubraca® (rucaparib) in multiple tumor types have
IMV Announces Selection of a Vaccine Candidate Against COVID-19 to Advance Into Human Clinical Studies
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced positive
Clovis Oncology Announces Pricing of Public Offering of Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of 11,090,000 shares of its common stock in an underwritten public offering at a price to the public of $8.05 per share, before
Clovis Oncology Announces Proposed Offering of Common Stock
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of common stock.
Clovis Oncology intends to offer, subject to market and other
Aurinia Pharmaceuticals to Present at 2020 RBC Capital Markets’ Virtual Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy
Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that the U.S. Food and Drug Administration (FDA) approved Rubraca® (rucaparib) tablets for the treatment of adult patients with a deleterious B